InsidersTradesSigma
ABIOMED INC Stock: price and directors' dealings · United States · SEC (Form 4)
Track the ABIOMED INC stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ABIOMED INC has logged 152 insider filings. The latest transaction was filed on 27 December 2022 (Disposition). Among the most active insiders: MINOGUE MICHAEL R. The full history is free.
152
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€12m
41 ops.
Sell Volume
39Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 27 December 2022
Declarations152 total
1,721 shares0Common Stock, $.01 par valueSEC:0001415889-22-012998:0
12,237 sharesCommon Stock, $0.01 par valueSEC:0001415889-22-013011:0
1,659 shares0Common Stock, $.01 par valueSEC:0001415889-22-013007:0
23,484 shares0Common Stock, $.01 par valueSEC:0001415889-22-013015:0
123,370 sharesCommon Stock, $0.01 par valueSEC:0001415889-22-013033:0
14,166 sharesCommon Stock, $0.01 par valueSEC:0001415889-22-013029:0
166,670 shares0Common Stock $.01 par valueSEC:0001415889-22-013017:0
7,410 shares0Common Stock, $.01 par valueSEC:0001415889-22-012995:0
6,357 sharesCommon Stock, $.01 par valueSEC:0001415889-22-013000:0
9,285 sharesCommon Stock, $0.01 par valueSEC:0001415889-22-013005:0
3,255 shares0Common Stock, $0.01 par valueSEC:0001415889-22-013031:0
8,406 shares0Common Stock $.01 par valueSEC:0001415889-22-013027:0
243,962 shares0Common Stock $.01 par valueSEC:0001415889-22-013017:1
11,335 shares0Common Stock, $0.01 par valueSEC:0001415889-22-013031:1
14 shares0Common Stock, $.01 par valueSEC:0001415889-22-012843:0
1 shares0Common Stock $.01 par valueSEC:0001415889-22-012840:0
1,133 shares@ US$374.182815.0% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011489:0
1,548 shares@ US$373.9925.0% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011176:0
5,164 shares@ US$373.9929.3% of flowCommon Stock $.01 par valueSEC:0001415889-22-011180:0
2,000 shares@ US$373.7139.6% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011186:0
1,548 shares@ US$373.9964.1% of flowCommon Stock, $.01 par valueSEC:0001415889-22-011183:0
1,548 shares@ US$373.9930.7% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011186:1
1,000 shares@ US$379.3850.6% of flowCommon Stock, $.01 par valueSEC:0001415889-22-011063:0
263 shares@ US$377.824.2% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011061:0
1,843 shares@ US$223.9066.2% of flowCommon Stock $.01 par valueSEC:0001415889-22-011065:0
25 of 152 declarations
About ABIOMED INC
ABIOMED INC. was historically a U.S. specialist in circulatory support and cardiac assist technologies and is now part of Johnson & Johnson MedTech. Prior to its acquisition, the company was listed on the U.S. NASDAQ market under the ticker ABMD and was best known for its Impella platform, a family of minimally invasive percutaneous heart pumps designed to temporarily unload the heart, maintain blood flow, and support patient recovery. Abiomed was founded in 1981 in Danvers, Massachusetts, with an original ambition to develop the world’s first artificial heart. Over time, its strategic focus evolved toward “native heart recovery,” meaning helping the patient’s own heart recover rather than permanently replacing cardiac function. The core product portfolio centered on the Impella family, including Impella CP, Impella 5.5, and Impella RP, along with SmartAssist-enabled versions and related clinical support offerings. These devices are used in high-risk PCI and cardiogenic shock settings, which positions ABIOMED in a highly specialized, clinically driven medtech niche. That niche is attractive from a competitive standpoint because it combines regulatory barriers, procedure-level expertise, and recurring clinician training and support. Abiomed also emphasized on-site, on-call, and online clinical services, which reinforced customer adoption and differentiated the platform from more commoditized medical-device offerings. Geographically, ABIOMED was anchored in the United States, with headquarters in Danvers, Massachusetts, and a steadily expanding international footprint, including Europe and Japan. The company’s history was marked by sustained innovation, a meaningful patent base, and a strong clinical-development pipeline. For investors, the most important recent milestone is the acquisition by Johnson & Johnson, announced in 2022 and completed on December 22, 2022. Following closing, Abiomed ceased to exist as an independent publicly traded company, and the business now operates as a standalone platform within Johnson & Johnson MedTech. From an equity-investor perspective, ABIOMED is therefore best understood as a former U.S. growth medtech company whose value proposition rested on breakthrough cardiovascular technology, strong clinical adoption, and intellectual-property depth. Although ABMD is no longer an active listed stock, Abiomed’s operating legacy remains strategically important inside Johnson & Johnson’s cardiovascular portfolio in the United States and internationally.
